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 Introduction 
 Colorectal cancer is a common malignancy and ranks 
as the 3rd most common cancer in both genders world-
wide. In 2011 it was estimated that more than 160,000 
patients died of colorectal cancer in Europe  [1] . Early re-
ports of local recurrence rates after curative resections of 
rectal cancer were as high as 38%  [2, 3] . In the last few 
decades, improvements in surgical technique have result-
ed in local recurrence rates less than 8%  [4, 5] . Today, the 
entire removal of the mesorectum by sharp dissection 
under visual control along the visceral fascia of the me-
sorectum and the parietal fascia of the pelvis is accepted 
as the standard approach in rectal cancer surgery and is 
referred to as total mesorectal excision (TME).
 Considerable debate has evolved about the signifi-
cance of preoperative radiotherapy with or without che-
motherapy in the treatment of resectable rectal cancer. 
Two meta-analyses evaluated the benefit of neoadjuvant 
radiotherapy  [6, 7] . They concluded that preoperative ra-
diation therapy was associated with significantly less lo-
cal recurrence. In the CAO/ARO/A10–94 trial, patients 
with stage II and III rectal cancer were randomly as-
signed to receive either preoperative or postoperative 
chemoradiotherapy  [8] . Preoperative chemoradiotherapy 
was associated with improved local control and less toxic-
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 Abstract 
 It is well known that some patients with resectable rectal 
cancer benefit from preoperative radiotherapy in combina-
tion with or without chemotherapy. In order to reduce local 
recurrence and improve long-term survival, current guide-
lines advocate such neoadjuvant treatment in UICC (Union 
for International Cancer Control) stage II and III patients. 
However, the vast majority of patients may be adequately 
treated by rectal resection with total mesorectal excision 
(TME) alone. Recent evidence suggests an overtreatment of 
patients leading to unnecessary exposure to acute and long-
term toxicity of radiation therapy. The question which con-
sequently arises is which patient does not need preoperative 
radiotherapy. Improvements in MRI combined with better 
understanding of prognostic indicators suggest that pa-
tients with UICC stage I tumors, with tumors more than 
12 cm proximal the anal verge can and patients with a cir-
cumferential resection margin  6 2 mm as assessed by pre-
operative MRI might be managed by radical surgery with ad-
equate TME alone. 
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ity. Furthermore, a statistically significant increase in 
sphincter preservation was achieved among patients after 
preoperative chemoradiation. Based on these results, 
guidelines in Germany advocate that rectal cancer pa-
tients with stage II and III disease after preoperative stag-
ing be given neoadjuvant radiotherapy or chemoradio-
therapy  [9] .
 However, the current classification system of rectal 
cancer patients as stage II and stage III has limitations. 
Patients with T3 tumors incorporate a heterogeneous 
group of patients with markedly different prognoses de-
pending on the extent of extramural tumor spread  [10–
12] . For the patient who is selected to receive neoadjuvant 
radiotherapy, the expected benefit and harm has to be 
well balanced. Side effects of radiotherapy such as fecal 
incontinence, sexual dysfunction, bowel dysfunction, 
and secondary malignancy can impair quality of life and 
shorten life expectancy  [13–18] . Routine, nonselective 
neoadjuvant treatment also has major financial implica-
tions for health care providers. Recent improvements in 
preoperative staging may offer possibilities to carefully 
identify the individual patient who does not need preop-
erative radiotherapy.
 Background 
 The following large randomized controlled studies in 
the TME era evaluated preoperative or postoperative ra-
diation therapy with or without chemotherapy.
 A Dutch trial randomly assigned 1861 patients with 
resectable rectal cancer to preoperative radiotherapy 
with 5  ! 5 Gy followed by TME within a week or to TME 
alone  [18] . The 10-year cumulative incidence of local re-
currence was significantly reduced by radiotherapy com-
pared to surgery alone (5 vs. 11%, p  ! 0.0001). Although 
patients without neoadjuvant treatment died more often 
from cancer, pretreated patients presented other causes of 
death – especially secondary carcinomas within the ra-
diation field – resulting in an equal overall survival in 
both groups. In a subgroup of patients with negative cir-
cumferential resection margin (CRM), only the patients 
with stage III disease benefited from preoperative radio-
therapy, possibly underscoring the relevance of neoadju-
vant radiotherapy in patients with positive nodal status. 
However, it has to be taken in consideration that the CRM 
was evaluated by the pathologist after the operation and 
not by MRI preoperatively  [19] . Furthermore, the quality 
of TME was completely inadequate in 24% of the patients 
 [19] , increasing the risk  of local recurrence especially in 
stage III disease. In  contrast, patients with negative cir-
cumferential margin (CRM) and stage I or II disease did 
not benefit from additional preoperative radiotherapy 
( table 1 ).
 Another recently published multicenter randomized 
trial randomly assigned 1,350 patients to neoadjuvant 
short-term radiotherapy or selective postoperative 
chemoradiotherapy  [20] . Patients were selected to receive 
either neoadjuvant treatment independent of tumor stage 
or postoperative chemoradiotherapy, if the histopatho-
logical CRM was involved in the group not receiving neo-
adjuvant treatment. Overall survival did not differ be-
tween groups. However, after 5 years, the local recurrence 
rate of patients following neoadjuvant irradiation was 
significantly reduced compared to patients after selective 
chemoradiotherapy (4.7 vs. 11.5%, p  ! 0.001).
Table 1.  Dutch trial [18]
n 10-year LR, % p 1 0-year OS, % p
RT + TME TME RT + TME TME
All patients 1,748 5 11 <0.0001 56 57 0.88
TNM I 507 <1 3 0.027 65 72 0.321
TNM II 491 5 8 0.212 50 55 0.242
TNM III 622 9 19 <0.0001 39 37 0.526
CRM-negative
TNM I 497 <1 3 0.027 65 72 0.293
TNM II 421 4 7 0.355 51 57 0.213
TNM III 435 5 17 <0.0001 50 40 0.032
RT  = Radiotherapy; LR = local recurrence; OS = overall survival.
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 Sauer et al. [8] demonstrated in their multicenter ran-
domized trial involving 823 patients a significant reduc-
tion in local recurrence and late toxic effects in patients 
with neoadjuvant chemoradiotherapy compared to post-
operative chemoradiotherapy. After 5 years, the local re-
currence rate in patients after preoperative chemoradio-
therapy was reported to be 6%, compared to 13% in the 
group assigned to postoperative treatment (p  1 0.006). 
Acute and late toxic grade 3 or 4 effects were significant-
ly more frequent in patients receiving postoperative 
chemoradiotherapy (40 vs. 27%, p  ! 0.001; 24 vs. 14%, 
p  1 0.01). Despite starting systemic treatment preopera-
tively, no statistically significant difference, neither in 
distant recurrence nor in disease-free or overall survival, 
could be demonstrated. Following preoperative staging 
evaluation, patients with stage II and III rectal cancer 
were recruited. Histopathological examination revealed 
that 8% of the patients assigned to the preoperative group 
became complete responders and 25% of the patients as-
signed to the preoperative group were stage I. This down-
staging can be attributed to the preoperative chemora-
diotherapy. However, 18% of the patients assigned to the 
postoperative chemoradiotherapy group were initially 
overstaged since histopathological examination revealed 
stage I disease.
 Radiotherapy and Its Side Effects 
 Radiotherapy can be associated with considerable side 
effects. The patient collective participating in the Dutch 
study was evaluated for late side effects of short-course 
preoperative radiotherapy  [17] . In patients without a sto-
ma, mean bowel frequency during the day was signifi-
cantly higher in irradiated patients compared to patients 
after surgery alone. The evaluated variables to determine 
the bowel function were fecal incontinence during the 
day and at night, anal blood and mucus loss, and higher 
rates of pad wearing. Irradiated patients were affected 
significantly more frequently by the reported variables. 
Other factors, such as impact of bowel function on daily 
activities or overall satisfaction with bowel function, were 
more frequently reported by irradiated patients, com-
pared to surgery-alone patients, but this difference did 
not reach statistical significance. No difference in satis-
faction between the two groups was noted in patients 
with a stoma.
 Bruheim et al. [15] evaluated the sexual function in 
males after radiotherapy for rectal cancer. Question-
naires were returned from 241 patients (108 patients after 
preoperative or postoperative (chemo)radiotherapy and 
133 patients without radiotherapy) a median of 4.5 years 
after rectal cancer surgery. Irradiated patients had sig-
nificantly poorer scores for erectile function, orgasmic 
function, intercourse satisfaction, and overall satisfaction 
with sex life compared with nonirradiated patients. Irra-
diated patients more often had pT4 tumors, more fre-
quent tumors closer to the anal verge, and more frequent 
abdominoperineal resections compared to the nonirradi-
ated patients. However, even after exclusion of patients 
with prostate, seminal vesicle, and pelvic floor resections, 
sexual function of irradiated patients remained poorer 
compared to nonirradiated patients.
 Radiotherapy causes additional long-term side effects 
and may impair quality of life. Besides that, radiotherapy 
may shorten life expectancy by causing secondary malig-
nancies. Secondary malignancy was reported to be the 
cause of death in 14% of patients after preoperative radio-
therapy prior to TME, compared to 9% after TME alone 
and a median follow-up of 10 years in the Dutch trial  [18] .
 Quality of Surgery 
 Surgery has been the cornerstone of treatment for pa-
tients with resectable rectal cancer. After the introduc-
tion of TME by Heald and Ryall  [5] , local recurrence after 
rectal cancer surgery dropped below 8%  [21] . Training in 
surgical technique to perform TME improved oncologi-
cal outcome in populations from Norway, Sweden, and 
the Netherlands  [22–24] . Quirke et al. [25] evaluated the 
involvement of the CRM and the quality of TME achieved 
in 1,156 patients with resectable rectal cancer from the 
Table 2.  Effect of plane of surgery achieved on 3-year local recur-
rence (%) [20]
Muscularis
propria
Intra-
mesorectal
Meso-
rectal
Overall 13 7 4
Treatment
Preoperative RT 10 4 1
Selective postop. CRT 16 10 7
TNM stage
I 8 2 0
II 6 2 5
III 20 14 6
R T = Radiotherapy; CRT = chemoradiotherapy.
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MRC CR07 trial. The quality of TME was strongly asso-
ciated with local recurrence. Local recurrence rates after 
3 years increased depending on the plane of surgery 
achieved from 4% if it was within the mesorectal plane, 
to 7% if it was within the intramesorectal plane, up to 13% 
if the resection plane was within the muscularis propria 
(log-rank p = 0.0039;  table 2 ). In the MRC CR07 trial, the 
use of TME was not mandated in the trial protocol. Con-
sequently, surgery within the mesorectal plane was 
achieved in only 52% of the patients. This suggests that a 
further decrease in local recurrence rates might be ob-
tained by improving the surgical plane achieved ( table 2 ).
 Tumor Height 
 There is still debate about the necessity to radiate pa-
tients with tumors of the upper third of the rectum. In 
the United States, high rectal cancers are treated like co-
lon cancer, whereas in many European countries, includ-
ing Germany, pretreatment is advocated. However, a 
subgroup analysis of the Dutch study revealed no sig-
nificant reduction of local recurrence rate by radiother-
apy in patients with rectal cancer more than 10 cm from 
the anal verge  [18] . The same is true for the patients treat-
ed within the Swedish Rectal Cancer Trial  [26] . Even not 
operated following the TME principles, patients with tu-
mors more than 11 cm from the anal verge had no sig-
nificant reduction of local recurrence if additionally sub-
jected to preoperative radiotherapy ( table 3 ). Nowadays, 
the majority of colorectal surgeons consider 12 cm from 
the anal verge as the beginning of the upper third of the 
rectum. Due to the limited effect of neoadjuvant treat-
ment in high rectal tumors, there is a tendency to omit 
neoadjuvant treatment.
 TNM Stage 
 In the Dutch trial comparing short-term radiotherapy 
followed by TME with TME alone, no significant differ-
ences were found for stage I and II disease in terms of lo-
cal recurrence and overall survival after 10 years  [18] . In 
contrast, patients with stage III disease and neoadjuvant 
treatment showed a significantly reduced rate of local re-
currence after 10 years (9 vs. 19%, p  ! 0.0001), though 
without survival benefit (10-year overall survival: 39 vs. 
37%, p = 0.526)  [18] . Only in a further subgroup analysis 
of patients with stage III disease and negative CRM could 
a significant survival benefit of 10% over 10 years be de-
tected. The disadvantage of the postoperative evaluation 
of the CRM compared to preoperative evaluation by MRI 
has been mentioned before. Interestingly, the same sub-
group analysis for stage I disease revealed a statistically 
significant risk reduction of 2.6% for local recurrence for 
patients with stage I tumors if subjected to neoadjuvant 
radiotherapy. It is common sense that patients with stage 
I disease should not undergo neoadjuvant treatment, dis-
playing the difficulties in the interpretation of subgroup 
analyses of further subgroup analyses. Consequently, the 
authors concluded that an absolute risk reduction of 2.6% 
for all eligible patients implies that 38 patients have to be 
exposed to radiotherapy to save 1 patient a local recur-
rence without any survival benefit ( table 1 ).
 Lymph Nodes Involved 
 The relevance of nodal status has been highlighted in 
a study by Hermanek et al.  [27] . They evaluated the rela-
tionship between the number of involved regional lymph 
nodes and the risk of locoregional recurrence. While 
there was no statistically significant difference in local 
Table 3.  Oncological outcome based on tumor location and TNM staging
Trial, year Study design LR, % p LR, % p LR, % p
Tumor location <5 cm 5–10 cm >10 cm
Dutch study 2011 [18] RT vs. TME 10.7 vs. 12 0.578 3.7 vs. 13.7 <0.0001 3.7 vs. 6.2 0.122
SRCT 1997 [37] RT vs. OP 10 vs. 27 0.003 9 vs. 26 <0.0001 8 vs. 12 0.3
TNM Staging UICC I UICC II UICC III
Dutch study 2011 RT vs. TME 0.4 vs. 14 0.091 5.3 vs. 7.2 0.331 10.6 vs. 20.6 <0.0001
SRCT 1997 RT vs. OP 4.5 vs. 14 0.009 6 vs. 22 <0.0001 23 vs. 46 <0.0001
L R = Local recurrence; RT = radiotherapy; OP = operation; SRCT = Swedish rectal cancer study; UICC = Union for International 
Cancer Control.
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recurrence between pN0 and pN1, there were highly sig-
nificant differences (p  ! 0.001) between pN1 and pN2. In 
patients with pN2 nodal status, the rate of local recur-
rence was about 30%. The authors concluded that in this 
patient collective, neoadjuvant treatment is indicated. 
However, preoperative lymph node assessment with the 
diagnostic tools available to date still lacks accuracy with 
a positive predictive value of about 60%. New diagnostic 
modalities to predict the presence of lymph nodes in-
volved are clearly warranted.
 Circumferential Margin 
 Another important variable to enable the preoperative 
differentiation of patients with good versus poor progno-
sis tumors is the determination of the circumferential tu-
mor margin involvement  [28] . In a recent work by Nag-
tegaal and Quirke  [29] , the relevance of CRM was evalu-
ated by reviewing the published data of 17,568 rectal 
cancer patients. The authors concluded that the power of 
the CRM to predict local recurrence and, to a lesser ex-
tent, development of distant metastases and survival is 
high, and that CRM involvement is one of the strongest 
prognosticators.
 In 1986, Quirke et al. [30]  demonstrated in their his-
topathological study the relevance of the CRM. Thor-
ough examination of operative specimens of 52 patients 
revealed that the sensitivity, specificity, and positive pre-
dictive value in predicting local recurrence were 92, 95, 
and 85%, respectively.
 Nonirradiated patients of the Dutch study were ana-
lyzed for CRM involvement and oncologic outcome  [19] . 
After a median follow-up of 35 months, a CRM of  ^  2 
mm was associated with a local recurrence risk of 16% 
compared with 5.8% in patients with a CRM of  6 2 mm 
(p  ! 0.0001). Within the first 2 years of follow-up, 37.6% 
of the patients with a CRM of  ^  1 mm developed distal 
metastases, whereas patients with a CRM of  6 1 mm
metastasized significantly less frequently (12.7%, p  ! 
0.0001). The relevance of CRM was also evaluated in pa-
tients who participated in the MRC CR07 study. Quirke 
et al. [25] assessed 1,156 patients and found that negative 
CRM was associated with a significantly reduced local 
recurrence rate (negative CRM vs. positive CRM: 6 vs. 
17%). The plane of surgery achieved was strongly associ-
ated with local recurrence. Subgroup analysis revealed 
that local recurrence rates after 3 years in patients with a 
stage III tumor was 20% if the surgical plane achieved was 
the muscularis propria, 14% in case of intramesorectal, 
and as low as 6% if the surgical plane achieved was the 
mesorectum.
 In addition to the above-mentioned evidence on the 
significance of CRM, extramural tumor spread influenc-
es prognosis  [12, 31–33] . Rectal cancers invading through 
the muscularis propria into subserosa or into nonperito-
nealized pericolic or perirectal tissues not directly invad-
ing other organs or structures nor perforating the vis-
ceral peritoneum are termed pT3. Merkel et al. [11] evalu-
ated 1,453 patients with pT3 rectal carcinomas who were 
treated by radical surgery alone and assessed for onco-
logical outcome depending on extramural spread. Pa-
tients with rectal cancer with a maximal tumor invasion 
beyond the outer border of the muscularis propria of up 
to 5 mm were categorized as pT3a, and more than 5 mm 
were categorized as pT3b. Local recurrence after 5 years 
was significantly less frequent in patients with pT3a rectal 
cancer, compared to patients with pT3b (10.4 vs. 26.3%, 
p  ! 0.0001). The cancer-related 5-year survival rates were 
85.4% for pT3a and 54.1% for pT3b (p  ! 0.0001). Compar-
ing the oncological outcome of patients with pT2 and pT4 
rectal cancer, no significant differences concerning local 
recurrence and cancer-related survival were observed be-
tween pT2 versus pT3a and pT3b versus pT4. Careful pre-
operative determination of extramural spread might 
identify the subgroup of patients with stage II rectal can-
cer (pT3apTN0) not in need of neoadjuvant treatment.
 The quintessence of the above-mentioned histopatho-
logical studies may well be that the benefit from preop-
erative treatment for patients who have tumors with less 
than 5 mm of extramural tumor spread is going to be 
minimal. In contrast to that, preoperatively identified pa-
tients with tumors with extensive tumor spread would 
most likely benefit from additional preoperative treat-
ment.
 To demonstrate the feasibility of preoperative deter-
mination of extramural tumor spread via thin sectioning 
MRI, a prospective multicenter study was initiated. The 
Magnetic Resonance Imaging and Rectal Cancer Euro-
pean Equivalence (MERCURY) study prospectively eval-
uated the accuracy of MRI in depicting the extramural 
spread of tumor invasion of patients with rectal cancer 
 [28] . The preoperative assessment was correlated with 
histopathological analysis. Evaluation of 295 patients 
with preoperative magnetic resonance and histopatho-
logical measurements revealed a mean extramural depth 
of invasion at MRI of 2.8 mm  8 4.6 and at histopatho-
logic examination of 2.81 mm  8 4.28. Therefore, mag-
netic resonance and histopathologic assessment of tumor 
spread were considered equivalent to within 0.5 mm.
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 Preoperative Staging and Radiotherapy 
 Simunovic et al. [34] demonstrated in their institu-
tional study of 150 patients that with preoperative clinical 
assessment of rectal cancer, preoperative irradiation can 
be spared in the majority of the patients. Based on assess-
ment of tumor size, fixation, and distance from anal 
verge, 115 patients (42.6% stage I/II, 33.9% stage III, and 
23.5% stage IV) were subjected to surgical resection with 
TME. After a median follow-up of 29 months, the local 
recurrence rate was 2.6%. Patients deemed to be at high 
risk of recurrence received radiotherapy. In this group
the local recurrence rate was 17.1%.
 In the framework of the MERCURY study, 122 pa-
tients were identified with rectal cancers defined as good 
prognosis tumor [tumor  1 1 mm to the mesorectal fascia, 
no evidence of extramural venous invasion on MRI, T1/
T2, T3a (less than 5 mm extramural spread)]  [35] . None 
of the patients received preoperative or postoperative ra-
diotherapy. The overall local recurrence after 5 years was 
3.3% ( table 4 ).
 Frasson et al. [36] assessed the factors that predict re-
currence in patients with cT3 and cT2N+ rectal cancer, 
staged preoperatively by endorectal ultrasonography 
and/or MRI. Threatened mesorectal fascia (free margin 
 ^  2 mm) at preoperative staging was the only significant 
independent preoperative factor for oncological outcome. 
Patients who had a threatened CRM or the CRM was not 
determined preoperatively had a higher risk for local re-
currence (19.4 vs. 5.4%, p = 0.07), shorter disease-free sur-
vival (52.7 vs. 69.4%, p = 0.07) and shorter cancer-specif-
ic survival (64.0 vs. 82.3%, p = 0.05) compared to patients 
with preoperatively evaluated negative CRM after 5 years.
 Discussion 
 Several clinical trials were conducted to find out how 
to improve oncologic outcome of rectal cancer patients. 
Before TME was introduced, local recurrence after sur-
gery alone was high. The Swedish Rectal Cancer Trial 
demonstrated a statistically significant reduction in local 
recurrence rate for patients after preoperative radiother-
apy compared to surgery alone (11 vs. 27%, p  ! 0.001), and 
a favorable overall survival benefit (58 vs. 48%, p  ! 0.004) 
 [26, 37] . Since surgery has been carried out within the 
correct anatomical layers, the role of radiotherapy with 
or without chemotherapy has been questioned.
 Patient selection is key.  The current guidelines indi-
cating neoadjuvant treatment for all patients with stage II 
and III rectal cancer have to be challenged. Based on the 
currently available data, 95 patients have to be radiated 
without any benefit to avoid local recurrence in 5 pa-
tients. At the same time, the treatment has no positive 
impact on overall survival, in part due to secondary car-
cinomas induced by radiotherapy. Furthermore, many ir-
radiated patients have to suffer from side effects like im-
paired stool and sexual function. Therefore, randomized 
trials have to be conducted to better identify patients ben-
efitting from pretreatment. Simunovic et al.  [34] and the 
MERCURY Study Group have shown that the preopera-
tive evaluation of the CRM by MRI could help to improve 
the selection of patients. In case of an anticipated negative 
CRM, neoadjuvant treatment might not be necessary. 
Randomized controlled trials have to be conducted to in-
vestigate this hypothesis.
 That preoperative treatment for patients with locally 
advanced rectal cancer which invades neighboring ana-
tomical structures is part of the multimodal therapy is 
out of question.
 Controversy still exists concerning the efficacy of ra-
diation in high rectal cancers above 12 cm from the anal 
verge. Preoperative radiotherapy could not reduce the 
rate of local recurrence or improve survival in these pa-
tients in the Dutch trial including TME  [35, 37] .
 If the surgeon follows the principles of TME, the rel-
evance of the nodal status alone is limited. There is sus-
picion that patients with pN2 have a greater risk of local 
Table 4.  Oncological outcome of recently reported series based
on AJCC staging
Treatment
received
LR
%
OS
%
Follow-up
years
Stage II
MERCURY [35] TME 2.3 65.7 5
MRC CR07 [20] pre-RT + TME 1.9 NA 3
TME + post-CRT 6.4 NA 3
Dutch study [18] TME 8 55 10
pre-RT + TME 5 50 10
Stage III
MERCURY TME 0 81 5
MRC CR07 pre-RT + TME 7.4 NA 3
TME + post-CRT 15.4 NA 3
Dutch study TME 17 40 10
pre-RT + TME 5 50 10
L R = Local recurrence; OS = overall survival; pre-RT = preop-
erative radiotherapy; post-CRT = postoperative chemoradiother-
apy.
 Kulu/Ulrich/Büchler
 
Dig Dis 2012;30(suppl 2):118–125124
recurrence; however, lymph node assessment during pre-
operative staging lacks accuracy  [27] . On the other hand, 
Cecil et al. [38] demonstrated that TME allows resection 
of all mesorectal lymph nodes, resulting in a favorable 
oncologic outcome, even without preoperative radiother-
apy. It is difficult to understand why the lymph node sta-
tus should play such an important role, if an adequate 
TME was performed, the preoperative CRM was negative 
and, therefore, the perirectal lymph nodes are resected 
completely. However, lateral lymph nodes, affected by the 
neoadjuvant treatment and not reached by TME, could 
make up for the difference.
 It is widespread policy that patients are subjected to 
postoperative radiochemotherapy if the histopathologi-
cal report proves a stage UICC II or III disease in preop-
eratively understaged patients. However, based on the re-
sults of the CAO/ARO/AIO-94 trial  [8] and the MRC-
CR07 trial  [20] , this has to be challenged. Postoperative 
radiotherapy causes side effects without any oncologic 
benefit. Its effectivity is limited and local recurrence rates 
are comparable to the rates achieved by TME alone.
 The prognostic relevance of the circumferential mar-
gin has been well documented  [29] . Taylor et al.  [35] dem-
onstrated in their study that in selected rectal cancer pa-
tients, identified by determination of the CRM and other 
good prognosis criteria using high-resolution MRI, local 
recurrence rates were as low as 3.3%. However, it has to 
be clearly differentiated between the preoperative evalu-
ation and the postoperative evaluation of the CRM by the 
pathologists. In case of an inadequate TME, both could 
be negative, though lymph node metastases within the 
mesorectum remained within the pelvis. This could ex-
plain the greater differences in local recurrence in the 
randomized trials to date in stage III rectal cancer.
 Conclusion 
 In the treatment of patients with rectal cancer, surgery 
remains the mainstay. Since radiotherapy and chemora-
diotherapy may improve local recurrence and survival in 
some patients, many patients with resectable rectal can-
cer are overtreated. Those patients are exposed to the 
risk of acute and long-term toxicity due to unnecessary 
radiotherapy. Subsets of patients who do not need preop-
erative radiotherapy need to be better defined. Accord-
ing to available evidence, those are patients with stage I 
tumors and tumors more than 12 cm proximal the anal 
verge. There is evidence that patients with a negative 
CRM ( 6 1–2 mm) as assessed by preoperative MRI might 
not benefit from neoadjuvant treatment. This hypothe-
sis, though, has to be proven by a randomized controlled 
trial.
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